Actinium Pharmaceuticals, Inc. (ATNM) has a negative trailing P/E of -1.0, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 2.5 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -97.42%, forward earnings yield 39.53%. PEG 0.01 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 54/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -1.7 | 0.20 | 2.35 | 0.00 | - |
| 2017 | -1.7 | 0.08 | 3.24 | 0.00 | - |
| 2018 | -1.7 | 0.04 | 4.66 | 0.00 | - |
| 2019 | -1.5 | 0.04 | 5.76 | 0.00 | 0.00% |
| 2020 | -4.3 | 0.07 | 1.54 | 0.00 | 0.00% |
| 2021 | -5.0 | 0.14 | 1.68 | 108.05 | - |
| 2022 | -7.8 | -0.55 | 3.87 | 249.62 | - |
| 2023 | -2.8 | -0.08 | 3.72 | 1,668.50 | - |
| 2024 | -1.0 | 0.03 | 1.16 | 0.00 | - |
| 2025 | -1.3 | 0.09 | 5.42 | 471.40 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-15.06 | $0.00 | $-24.32M | - |
| 2017 | $-11.96 | $0.00 | $-26.6M | - |
| 2018 | $-6.69 | $0.00 | $-23.65M | - |
| 2019 | $-4.37 | $0.00 | $-21.73M | - |
| 2020 | $-1.82 | $0.00 | $-22.04M | - |
| 2021 | $-1.20 | $1.14M | $-24.58M | -2149% |
| 2022 | $-1.37 | $1.03M | $-33.02M | -3205.5% |
| 2023 | $-1.83 | $81K | $-48.82M | -60269.1% |
| 2024 | $-1.27 | $0.00 | $-38.24M | - |
| 2025 | $-1.09 | $90K | $-33.89M | -37652.2% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.98 | $-0.98 – $-0.98 | $12.91M | $12.91M – $12.91M | 2 |
| 2027 | $-0.93 | $-0.93 – $-0.93 | $38.78M | $38.78M – $38.78M | 2 |
| 2028 | $-0.99 | $-3.79 – $4.18 | $12.29M | $12.29M – $12.29M | 4 |
| 2029 | $-0.89 | $-0.89 – $-0.89 | $69.94M | $69.94M – $69.94M | 2 |
| 2030 | $-0.95 | $-0.95 – $-0.95 | $131.98M | $131.98M – $131.98M | 2 |
